Compared side by side
Semaglutide vs exenatide: how they differ
The short answer
Both are GLP-1 receptor agonists, and exenatide, a copy of exendin-4 from Gila monster venom, was the first approved; with a half-life of about 2.4 hours it is a shot before the two main meals, while semaglutide lasts about a week and is taken weekly. Exenatide was FDA-approved in 2005, as Byetta, for blood sugar control in type 2 diabetes, and its US products are being discontinued; semaglutide is FDA-approved for type 2 diabetes and weight management, as Ozempic and Wegovy. Exenatide’s effect on weight was about 3 kg in its 24- to 30-week trials, and semaglutide averaged about 15% weight loss at 68 weeks in its main trial.
Side by side
| Compared | Semaglutide | Exenatide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Ozempic, Wegovy | Byetta, Exendin-4, AC2993 |
| What it is | A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying. | The first GLP-1 drug, made from a peptide found in Gila monster venom, approved in 2005 as Byetta for type 2 diabetes: a shot before breakfast and dinner that lowers blood sugar after meals. |
| How it works | GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects. | The first GLP-1 receptor agonist approved: a synthetic copy of exendin-4, a 39-amino-acid peptide first found in the venom of the Gila monster, whose sequence partly overlaps human GLP-1. It releases insulin when glucose is high, lowers glucagon and slows stomach emptying, and it reduces food intake. It is cleared by the kidneys with a half-life of about 2.4 hours, so the original form (Byetta) is a shot before the two main meals of the day. FDA-approved in 2005 for type 2 diabetes in adults; it is not approved for weight management, and every US exenatide product is now listed as discontinued. |
| Commonly reported | The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial. | A smaller appetite and nausea in the first weeks, easing for most people with time. Every US exenatide product, including the weekly Bydureon BCise, is now listed by the FDA as discontinued. |
| Studied range | FDA label: 0.25–2.4 mg, starting dose 0.25 mg. | FDA label: 5–10 mcg, starting dose 5 mcg. |
| How often | Weekly SubQ | Twice daily SubQ, before meals |
| Half-life | ~1 week (FDA label) | ~2.4 hours (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers. | FDA-approved for ongoing use in type 2 diabetes; the label's trials ran 16 to 30 weeks, with open-label extensions to 52 weeks. The once-weekly extended-release form (Bydureon, later Bydureon BCise) was studied for a median of 3.2 years in EXSCEL. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk | Nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, indigestion, low blood sugar (with a sulfonylurea or insulin) |
- Category
- SemaglutideMetabolic & GLP-1
- ExenatideMetabolic & GLP-1
- Also known as
- SemaglutideOzempic, Wegovy
- ExenatideByetta, Exendin-4, AC2993
- What it is
- SemaglutideA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.
- ExenatideThe first GLP-1 drug, made from a peptide found in Gila monster venom, approved in 2005 as Byetta for type 2 diabetes: a shot before breakfast and dinner that lowers blood sugar after meals.
- How it works
- SemaglutideGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.
- ExenatideThe first GLP-1 receptor agonist approved: a synthetic copy of exendin-4, a 39-amino-acid peptide first found in the venom of the Gila monster, whose sequence partly overlaps human GLP-1. It releases insulin when glucose is high, lowers glucagon and slows stomach emptying, and it reduces food intake. It is cleared by the kidneys with a half-life of about 2.4 hours, so the original form (Byetta) is a shot before the two main meals of the day. FDA-approved in 2005 for type 2 diabetes in adults; it is not approved for weight management, and every US exenatide product is now listed as discontinued.
- Commonly reported
- SemaglutideThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.
- ExenatideA smaller appetite and nausea in the first weeks, easing for most people with time. Every US exenatide product, including the weekly Bydureon BCise, is now listed by the FDA as discontinued.
- Studied range
- SemaglutideFDA label: 0.25–2.4 mg, starting dose 0.25 mg.
- ExenatideFDA label: 5–10 mcg, starting dose 5 mcg.
- How often
- SemaglutideWeekly SubQ
- ExenatideTwice daily SubQ, before meals
- Half-life
- Semaglutide~1 week (FDA label)
- Exenatide~2.4 hours (FDA label)
- Route
- SemaglutideSubQ injection
- ExenatideSubQ injection
- Typical run
- SemaglutideFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.
- ExenatideFDA-approved for ongoing use in type 2 diabetes; the label's trials ran 16 to 30 weeks, with open-label extensions to 52 weeks. The once-weekly extended-release form (Bydureon, later Bydureon BCise) was studied for a median of 3.2 years in EXSCEL.
- Evidence
- SemaglutideEstablished: clinical trials or FDA-approved use exists
- ExenatideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- SemaglutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk
- ExenatideNausea, vomiting, diarrhea, feeling jittery, dizziness, headache, indigestion, low blood sugar (with a sulfonylurea or insulin)
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Semaglutide
- Day 1–28 · 0.25 mg Gut is adapting
- Day 29–56 · 0.5 mg Appetite shifts are real now
- Day 57–112 · 1 mg Clinically useful weight loss kicks in
- Day 113–140 · 1.7 mg Max submaximal step
- Day 141–364 · 2.4 mg Full dose — the working dose
- Day 365+ Plateau territory — new baseline
Exenatide
- Day 1–30 · 5 mcg The 5 mcg start, before two meals
- Day 1–60 Why the shot comes before the meal
- Day 31–180 · 10 mcg 10 mcg, the full dose
- Day 181+ A medicine the market moved past
Questions people ask
How long do semaglutide and exenatide last?
The half-life of semaglutide is ~1 week (FDA label). The half-life of exenatide is ~2.4 hours (FDA label).
How often are semaglutide and exenatide taken?
Semaglutide: weekly SubQ. Route: SubQ injection. Exenatide: twice daily SubQ, before meals. Route: SubQ injection.
How are semaglutide and exenatide dosed in research?
The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The FDA label range for exenatide is 5–10 mcg, with a 5 mcg starting dose.
What are the common side effects of semaglutide and exenatide?
For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For exenatide: nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, indigestion, low blood sugar (with a sulfonylurea or insulin).